文献速递血栓与止血

使用去糖基化KKO治疗小鼠肝素诱导的血小板减少症中的血小板减少和血栓形成:一种新疗法?

Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic?
PubMed 文献 · Blood Adv · 2023-01-01

本研究在小鼠模型中探讨去糖基化KKO(DGKKO)对肝素诱导的血小板减少症(HIT)的治疗作用。DGKKO保留结合PF4-多阴离子复合物的能力,抑制FcγRIIA依赖的血小板活化和补体沉积,并在HIT小鼠中预防和逆转血小板减少及血栓生长,但对疫苗诱导免疫血栓性血小板减少症IgG无效。

要点

  • DGKKO保留与PF4-多阴离子复合物结合,抑制HIT抗体诱导的血小板活化。
  • 在HIT小鼠中,DGKKO预防和逆转血小板减少及血栓生长。
  • DGKKO对VITT相关IgG诱导的血栓形成无效。

核心结论

  • DGKKO可能代表一类用于靶向治疗HIT患者的新疗法。

研究设计与样本

  • 使用EndoS制备去糖基化KKO(DGKKO),在缺乏小鼠PF4但转基因表达人PF4和FcγRIIA的HIT小鼠模型中评估其作用。

主要发现

  • DGKKO保留与PF4-多阴离子复合物结合,抑制未修饰KKO、5B9及HIT患者IgG触发的FcγRIIA依赖的血小板活化。
  • DGKKO减少补体活化和血小板表面C3c沉积。
  • 在HIT小鼠中,注射DGKKO(先于或后于未修饰KKO、5B9或HIT IgG)预防和逆转血小板减少,并逆转抗体诱导的血栓生长。
  • DGKKO对疫苗诱导免疫血栓性血小板减少症(VITT)患者IgG诱导的血栓形成无效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is characterized by thrombocytopenia associated with a highly prothrombotic state due to the development of pathogenic antibodies that recognize human platelet factor 4 (hPF4) complexed with various polyanions. Although nonheparin anticoagulants are the mainstay of care in HIT, subsequent bleeding may develop, and the risk of developing new thromboembolic events remain. We previously described a mouse immunoglobulin G2bκ (IgG2bκ) antibody KKO that mimics the sentinel features of pathogenic HIT antibodies, including binding to the same neoepitope on hPF4-polyanion complexes. KKO, like HIT IgGs, activates platelets through FcγRIIA and induces complement activation. We then questioned whether Fc-modified KKO could be used as a novel therapeutic to prevent or treat HIT. Using the endoglycosidase EndoS, we created deglycosylated KKO (DGKKO). Although DGKKO retained binding to PF4-polyanion complexes, it inhibited FcγRIIA-dependent activation of PF4-treated platelets triggered by unmodified KKO, 5B9 (another HIT-like monoclonal antibody), and IgGs isolated from patients with HIT. DGKKO also decreased complement activation and deposition of C3c on platelets. Unlike the anticoagulant fondaparinux, injection of DGKKO into HIT mice lacking mouse PF4, but transgenic for hPF4 and FcγRIIA, prevented and reversed thrombocytopenia when injected before or after unmodified KKO, 5B9, or HIT IgG. DGKKO also reversed antibody-induced thrombus growth in HIT mice. In contrast, DGKKO was ineffective in preventing thrombosis induced by IgG from patients with the HIT-related anti-PF4 prothrombotic disorder, vaccine-induced immune thrombotic thrombocytopenia. Thus, DGKKO may represent a new class of therapeutics for targeted treatment of patients with HIT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sarkar A, Khandelwal S, Koma GT, et al. Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? Blood Adv. 2023. PMID: 37196641. doi:10.1182/bloodadvances.2023009661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。